Rigel Pharmaceuticals, Inc. (RIGL)

Rigel Pharmaceuticals Cash Flow Statement

Financials in millions USD. Fiscal year is January - December.

Fiscal Year	FY 2025	FY 2024	FY 2023	FY 2022	FY 2021
Period Ending	Dec 31, 2025	Dec 31, 2024	Dec 31, 2023	Dec 31, 2022	Dec 31, 2021
Net Income	367.02	17.49	-25.09	-58.57	-17.91
Depreciation & Amortization	2.42	2.23	1.24	1	1.16
Stock-Based Compensation	12.71	12.39	8.81	12.39	9.49
Other Adjustments	-286.98	-0.79	-0.21	0.48	3.43
Change in Receivables	-10.15	-11.07	9.77	-24.85	0.5
Changes in Inventories	-5.64	0.76	1.17	-2.38	-4.88
Changes in Accounts Payable	3.85	-3.8	-0.37	3.79	0.04
Changes in Accrued Expenses	2.94	7.02	-6.59	-2.79	6.57
Changes in Unearned Revenue	1.28	10.76	3.54	3	1.43
Changes in Other Operating Activities	-11.8	-3.52	2	-5.82	6.05
Operating Cash Flow	75.66	31.47	-5.74	-73.76	5.88
Operating Cash Flow Growth	140.40%	-	-	-	-
Capital Expenditures	-	-0.04	-	-0.45	-0.63
Sale of Property, Plant & Equipment	-	0.1	0.26	0.89	-
Purchases of Intangible Assets	-	-0.36	-15	-	-
Purchases of Investments	-153.49	-35.27	-31.21	-28.89	-141.46
Proceeds from Sale of Investments	61.13	39.7	41.65	101.23	62.05
Investing Cash Flow	-92.37	4.13	-4.3	72.78	-80.04
Long-Term Debt Issued	-	-	19.95	19.54	-
Long-Term Debt Repaid	-7.5	-	-	-	-
Net Long-Term Debt Issued (Repaid)	-7.5	-	19.95	19.54	-
Issuance of Common Stock	8.1	1.96	1.05	2.12	4.78
Net Common Stock Issued (Repurchased)	8.1	1.96	1.05	2.12	4.78
Other Financing Activities	-	-13.61	-2.63	-15.12	57.9
Financing Cash Flow	0.6	-11.64	18.37	6.55	62.68
Net Cash Flow	-16.11	23.96	8.33	5.57	-11.48
Free Cash Flow	75.66	31.44	-5.74	-74.21	5.25
Free Cash Flow Growth	140.67%	-	-	-	-
FCF Margin	25.71%	17.53%	-4.91%	-61.72%	3.52%
Free Cash Flow Per Share	4.02	1.78	-0.33	-4.35	0.31
Levered Free Cash Flow	352.58	30.9	-4.16	-42.68	-8.16
Unlevered Free Cash Flow	371.04	36.44	-19.51	-59.2	-3.18

Updated Mar 3, 2026. Data Source: Fiscal.ai. Standard template. Financial Sources.

SEC Filings: 10-K · 10-Q